The hypoxia-responsive long non-coding RNAs may impact on the tumor biology and subsequent management of breast cancer
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16370%2F18%3A43877062" target="_blank" >RIV/62157124:16370/18:43877062 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1016/j.biopha.2017.12.104" target="_blank" >http://dx.doi.org/10.1016/j.biopha.2017.12.104</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.biopha.2017.12.104" target="_blank" >10.1016/j.biopha.2017.12.104</a>
Alternative languages
Result language
angličtina
Original language name
The hypoxia-responsive long non-coding RNAs may impact on the tumor biology and subsequent management of breast cancer
Original language description
Long non-coding RNAs (lncRNAs) are DNA transcripts longer than 200 nucleotides without protein-coding potential. As they are key regulators of gene expression at chromatic, transcriptional and posttranscriptional level, they play important role in various biological and pathological processes. Dysregulation of lncRNAs has been observed in several diseases including cancer. Breast cancer is heterogeneous disease with many molecular subtypes specific in different prognosis and treatment responses. Hypoxia, a common micro-environmental feature of rapidly growing tumour is associated with metastases, recurrences and resistance to therapy. Aberrant expression of hypoxia related lncRNAs significantly correlates with poor outcomes in cancer patients, as the lncRNAs play an important regulatory role in the breast cancer-cell survival. Thus, a better understanding of lncRNAs role in the hypoxic conditions of breast cancer is crucial for precise understanding of the tumorigenesis, disease features and poor clinical outcome, especially in highly aggressive breast cancer subtypes (HER2-positive and triple-negative types). Moreover, lncRNAs may represent tumour marker predicting prognosis and therapeutic targets improving precise and personalized therapy for better patient's survival. In this review, we summarize the recent information on lncRNAs in breast cancer with special focus on the hypoxia-responsive lncRNAs and their potential impact on the prognosis, therapy algorithms and individual outcomes. Presented data helps in better understanding of the specific mechanisms predicting new therapeutic agents and strategies for the pharmacological intervention.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30107 - Medicinal chemistry
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Biomedicine & pharmacotherapy
ISSN
0753-3322
e-ISSN
—
Volume of the periodical
99
Issue of the periodical within the volume
March
Country of publishing house
FR - FRANCE
Number of pages
8
Pages from-to
51-58
UT code for WoS article
000427436800007
EID of the result in the Scopus database
2-s2.0-85040349129